07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

14-type high-risk HPV test regulatory update

Hologic said the Netherlands Society for Pathology approved the use of the company's Cervista HPV HR test for detecting HPV in the Dutch national cervical screening program. The test has CE Mark approval in the...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Hologic sales and marketing update

Hologic will launch its Cervista high throughput automation (HTA) system in the U.S. this month for use with its Cervista HPV HR test for cervical cancer screening. The Cervista HTA system, which Hologic plans to...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Clinical News

14-type high-risk HPV test: Final post-marketing study data

Final data from the Chinese post-marketing SHENCCAST II trial in 8,435 women showed that sensitivity for the identification of confirmed cervical intraepithelial neoplasia grade 2+ (CIN2+) was statistically equivalent for Cervista HPV HR test and...
07:00 , Apr 5, 2010 |  BC Week In Review  |  Clinical News

14-type high-risk HPV test: Interim post-marketing study data

Interim data from 5,043 patients in the Chinese post-marketing SHENCCAST II trial in >10,000 women showed that Hologic's Cervista HPV HR test had 90.7% sensitivity and 90.2% specificity for histologically confirmed cervical intraepithelial neoplasia grade...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Clinical News

16/18 genotyping HPV test regulatory update

The National Comprehensive Cancer Network (NCCN) updated its clinical practice guidelines in oncology for cervical cancer screening to recommend that a HPV 16/18 DNA test should complement cervical cancer screening methods, such as regular Pap...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Clinical News

16/18 genotyping HPV test regulatory update

FDA approved a PMA from Hologic for its Cervista HPV 16/18 test as an adjunct with the Cervista HPV HR test to detect HPV types 16 and 18 infection in women ages 30 and older...
07:00 , Mar 23, 2009 |  BC Week In Review  |  Clinical News

14-type high-risk HPV test regulatory update

FDA approved a PMA from Hologic for its Cervista HPV HR test to detect 14 high-risk types of human papillomavirus (HPV) infection in women ages 30 and older and to screen patients whose Pap smears...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

14-type high-risk HPV test diagnostic data

A U.S. study in >4,000 women showed that Cervista HPV detected 100% of grade 3 cervical intraepithelial neoplasia (CIN3), with a negative predictive value of 100%. The test had a 92.8% sensitivity for CIN2/3, with...
07:00 , Jun 16, 2008 |  BC Week In Review  |  Company News

Hologic, Third Wave deal

Hologic will acquire fellow diagnostics company Third Wave for $11.25 per share, or about $580 million in cash. The price is a 7% premium to Third Wave’s close of $10.50 on June 6, the last...
01:28 , Jun 10, 2008 |  BC Extra  |  Top Story

Hologic to acquire Third Wave

Hologic (NASDAQ:HOLX) will acquire fellow diagnostics company Third Wave (NASDAQ:TWTI) for $11.25 per share, or about $580 million in cash. The price is a 7% premium to Third Wave's close of $10.50 on Friday, the...